Please login to the form below

Not currently logged in
Email:
Password:

COPD

This page shows the latest COPD news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

Last year, AZ also paid 25m upfront in a research deal with German biotech Ethris to develop mRNA drugs for respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic

Latest news

  • Chiesi targets patient adherence via mobile app Chiesi targets patient adherence via mobile app

    Chiesi targets patient adherence via mobile app. Initiative will see asthma and COPD patients receive device training support. ... Chiesi Limited, the UK affiliate of Italian healthcare company Chiesi Farmaceutici, has launched a new mobile app for adult

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    AZ’ s Fasenra hit by COPD trial failure. Results give advantage to respiratory rivals GSK. ... exacerbations – a sudden worsening of symptoms – in moderate to very severe chronic obstructive pulmonary disease (COPD) patients.

  • Regeneron’s Dupixent and Praluent fall short Regeneron’s Dupixent and Praluent fall short

    such as asthma, nasal polyps and chronic obstructive pulmonary disease (COPD) “means there is a remarkably broad and deep pipeline within Dupixent itself”.

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    GSK gets maintenance indication for Trelegy. Will now treat airflow obstruction in COPD patients. ... The FDA green light comes on the back of the IMPACT trial which showed Trelegy could reduce exacerbations and other endpoints such as hospitalisations

  • FDA hands GSK a reprieve by blocking Novartis generic FDA hands GSK a reprieve by blocking Novartis generic

    Earlier this week GSK said it was factoring in the possibility of generic challengers to the chronic obstructive pulmonary disease (COPD) and asthma blockbuster in the US this year, despite regulatory ... The delay to Novartis’generic therefore looks

More from news
Approximately 74 fully matching, plus 225 partially matching documents found.

Latest Intelligence

  • Open minds for open innovation Open minds for open innovation

    And a couple of years ago, Novartis and the COPD Foundation’s crowd-shaped project won Communique’s Innovation in Healthcare Communications Award!

  • Significant figures Significant figures

    NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or bronchiectasis.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its ... The category has also seen the recent introduction of a major drug class

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Combine asthma with other respiratory diseases, including chronic obstructive pulmonary disease (COPD), and it contributes to more than 4 million deaths every single year, a stagnated figure that has seen no ... This year, Circassia established a

  • The cultural construction of illness The cultural construction of illness

    Work we conducted on COPD (Chronic obstructive pulmonary disease) in the US demonstrated this. ... There was an assumption among many people working in the category that the nature of COPD needed to be played down.

More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics